Top 5 Drug Type | Count |
---|---|
Small molecule drug | 47 |
CAR-T | 11 |
Chemical drugs | 9 |
Autologous CAR-T | 9 |
Monoclonal antibody | 8 |
Target |
Mechanism Tubulin inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date29 Dec 1992 |
Mechanism ALK inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date03 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Paclitaxel ( Tubulin ) | High grade glioma More | Phase 3 |
Anti-CD19 CART cell therapy (YaKe Biotechnology) ( CD19 ) | Visible Lesion More | Phase 2 Clinical |
Anti-CD7 CAR-T cell therapy (Yake Biotechnology) ( CD7 ) | CD7 positive Hematologic Neoplasms More | Phase 2 |
Chrysanthemum Shuxin Tablets | Angina, Stable More | Phase 2 |
Xinyu Patch | Recurrent aphthous ulcer More | Phase 2 |